Side effects and related matters that patients with lung cancer need to pay attention to when using platinib

Platinib, as a targeted therapy for lung cancer, is particularly suitable for patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). However, like other drugs, platinib may also produce a series of side effects during use, which requires patients and doctors to pay close attention.

1. Common side effects of platinib

1.Gastrointestinal reactions: including abdominal pain, diarrhea, loss of appetite, etc. These reactions may be related to the irritation of the gastrointestinal mucosa by the drug. For example, in one study, some of the 438 patients with solid tumors with RET mutations who were treated with 400mg once-daily oral platinib as monotherapy experienced gastrointestinal-related side effects.

2.Hypertension: Platinib may cause an increase in blood pressure, so patients should monitor their blood pressure regularly during medication and take antihypertensive measures if necessary. If high blood pressure cannot be effectively controlled, medication dosage may need to be adjusted or treatment may need to be suspended.

3.Hematological side effects: including thrombocytopenia, hemoglobin reduction, lymphocyte reduction, etc. These changes may affect the patient's coagulation function and immune function, so routine blood indicators need to be monitored regularly.

4. Abnormal liver function: manifested by elevated alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase. This may be due to the drug's effect on the metabolic and excretory functions of the liver. Patients should have their liver function checked regularly while taking platinib to ensure that the drug is not causing excessive damage to the liver.

5.Interstitial lung disease (ILD)/Non-infectious pneumonia: This is a serious and potentially life-threatening side effect. If patients develop symptoms such as difficulty breathing, cough, and fever, they should stop taking Platinib immediately and seek medical attention. In some cases, ILD may lead to permanent discontinuation of the drug.

6. Bleeding events: Some patients may experience bleeding events, such as epistaxis, hematuria, etc. after using platinib. Severe or life-threatening bleeding events require special attention and may require permanent discontinuation of the drug.

2. Precautions when using Platinib

1.Dose adjustment: The recommended dose of platinib is400mg, taken orally once a day on an empty stomach. However, specific dosages may be adjusted based on the patient's specific condition and tolerance. Doctors will adjust the dosage based on the patient's response and side effects to ensure the safety and effectiveness of the treatment.

2.Dietary adjustment: Patients should avoid excessive intake of fats and sugars while taking platinib to reduce physical burden and the risk of indigestion. At the same time, you should avoid eating foods that may contain carcinogens, such as smoked, grilled, fried and other foods.

3.Regular monitoring: Patients should undergo relevant examinations regularly during the use of platinib, including monitoring of physiological parameters such as blood routine and liver function. These tests can help identify and treat potential side effects and problems promptly.

4.Communication with doctors: Patients should maintain close communication with their doctors during the use of platinib. If any discomfort or abnormal reaction occurs, the doctor should be informed immediately so that the treatment plan can be adjusted in time.

5.Psychological adjustment: Lung cancer is a chronic disease, and the treatment process is long and painful. Patients should maintain an optimistic attitude, face the disease actively, and believe in scientific treatment methods. A good psychological state helps improve treatment effects and quality of life.